.

Previous Requests - October 2017

Date     Reference

Question(s)

Response 
02/10/2017 704/17

1. IM&T, IS, ICT Strategy 2016 (Not Clinical Strategy)

2. IM&T, IS, ICT Business/Departmental Plan 2017/18- Update/Version

3. IM&T, IS, ICT Department Org Chart

Click here for Response
02/10/2017 705/17

I would like to make a freedom of information request in relation to the recovery plan scheme (referred to as JSw3) in the minutes of 05 May 2017 in relation to the psychodynamic psychotherapy service provided by Derbyshire healthcare trust. I would like to request access to the recovery plan proposal, and review of evidence on which this proposal was based and subsequently considered.

Click here for Response

Please contact us to obtain copies of attachments

03/10/2017 706/17

I write as a UNITE Union Rep and (also a clinician)  to request a copy under the freedom of information act of a review conducted by Mental Health Commissioners into the provision of Psychological Therapies by Derbyshire NHS Healthcare Foundation Trust.

Click here for Response

Please contact us to obtain copies of attachments

09/10/2017 707/17

We request information in relation to the following medicines which are marketed for the treatment of chronic obstructive pulmonary disease:

a. Anoro (vilanterol and umeclidinium) which is marketed by GlaxoSmithKline
b. Braltus (tiotropium) which is marketed by Teva
c. Duaklir (aclidinium bromide and formoterol fumarate dihydrate) which is marketed by Astra Zeneca
d. Eklira (aclidinium)  which is marketed by Astra Zeneca
e. Incruse (umeclidinium) which is marketed by GlaxoSmithKline
f. Seebri (glycopyrronium) which is marketed by Novartis
g. Spiolto (tiotropium and olodaterol) which is marketed by Boehringer Ingelheim
h. Spiriva (tiotropium) which is marketed by Boehringer Ingelheim
i. Trimbow (formoterol fumarate dihydrate, beclometasone dipropionate and glycopyrronium (as bromide) which is marketed by Chiesi
j. Ultibro (indacaterol and glycopyrronium) which is marketed by Novartis or Pfizer (the “COPD Medicines”).

In respect of each of the COPD Medicines, please provide us with the following information:

1. A copy of any agreement relating to a rebate, discount, patient access, risk-sharing or other pricing scheme entered into by Southern Derbyshire CCG in relation to the COPD Medicines which results in Southern Derbyshire CCG paying less than the NHS list price for such COPD Medicines (whether by way of discount, rebate etc.).  

2. A copy of any communications between Southern Derbyshire CCG and the company or companies marketing such COPD Medicine in relation to such scheme.

3. Any information or requests sent to GP practices comprised within the CCG in the 6 months since contract signature with respect to such COPD Medicines schemes.

Click here for Response
11/10/2017  708/17

1. Since the creation of CCGs in 2013 following the Health and Social Care Act in 2012, has the NHS Southern Derbyshire CCG merged with any other CCGs?

2. Does the organisation use an external provider for VAT advisory services? If so please state the name of the organisation used (eg. Ernst Young, Berthold Bauer, Liaison, CRS, KPMG, RSM etc.)?

a. Please state the contract start and end date or review period.
b. Please confirm the total value of VAT recovered by the provider in 2016/17
c. Please state the total amount spent by the organisation for these services in 2016/17

3. Did the organisation use an external provider to re-review VAT recovered in the last financial year (16/17)? If so please state the name of the company used.

4. Please state the total number of Accounts Payable invoices processed by the organisation in the last financial year (16/17).

5. Please state the total value of Accounts Payable invoices in the last financial year (16/17).

6. Which Finance system is used by NHS Southern Derbyshire CCG (Oracle, Agresso, Sage, E-Financial, SAP etc.)?

7. How many active suppliers are currently on the Supplier Masterfile?

8. How many inactive suppliers are currently on the Supplier Masterfile?

9. Is 3rd party pre-payment software utilised by NHS Southern Derbyshire CCG to prevent invoice payment errors from occurring? If so, please provide contract period.

10. Since 2013, please state the name(s) of all external organisation(s) used to review AP and identify and recover erroneous payments, and the period(s) reviewed by each.

a. Please state the total value of moneys recovered by each provider in the period(s) reviewed.
b. Please state the total amount paid to any external parties/ total cost to of utilising these services, for this review work. 

11. Do you use any external provider to ensure invoices correlate to the contract charges i.e. checking volume discounts have been applied (please state name)? What % fee or rates does the trust pay for this service?

12. What is the annual spend on agency staff during the last financial year – broken down by staffing category?

13. How many contracts are currently active at the CCG?

14. What internal controls does NHS Southern Derbyshire CCG have to prevent payment errors occurring (3 way matching, no PO no PAY, invoice scanning etc.)?

15. Please provide a current CCG contact list/organisations structure for finance & procurement departments.

16. Does NHS Southern Derbyshire CCG conduct supplier statement reconciliation exercises on any suppliers? If so, what selection criteria is adhered to?

Click here for Response

Click here for Attachment

11/10/2017 709/17

1. Do you currently have any enhanced (non GMS or PMS) service contracts involving prostate cancer and/or Leuteinising Hormone-Releasing Hormone Analogue (LHRHA) administration with GP practices?

2. Does this service involve payments for the administration of the following LHRHAs? Please indicate which.

  • Zoladex (Goserelin)
  • Prostap (Leuprorelin)
  • Decapeptyl (Triptorelin)

3. What is the frequency of payment?

4. What is the payment amount?

5. Does the service include other factors such as:

  • PSA?
  • Symptom questionnaires?
  • Patient review follow ups?

6. Is there a specific payment for this?

Click here for Response
17/10/2017 710/17

1. In your area, how many people with possible autism who were referred for a diagnostic assessment had the assessment started within 3 months of their referral? Please provide this information as a number and as a percentage.

2. What was a) the median and b) the longest wait for the start of the diagnostic assessment?

3. Out of those who received a diagnosis of an autistic spectrum condition in 2016/17, what was the median time from referral to final diagnosis?

4. Out of those who received a diagnosis of an autistic spectrum condition in 2016/17, what was the longest time from referral to final diagnosis?

5. How many people were referred for an assessment in the year 2016/17, but have not yet received a diagnosis as of 1 October 2017? Please provide this information as a number and as a percentage.

6. As of October 2017, what is the current waiting time from referral to the start of the diagnostic assessment?

7. As of October 2017, what is the expected waiting time from referral to a final diagnosis of autism?

Click here for Response
19/10/2017 711/17

1. How many subject access requests did you receive the identifying paperwork for and process in 2014?

2. How many subject access requests did you receive the identifying paperwork for and process in 2015?

3. How many subject access requests did you receive the identifying paperwork for and process in 2016?

4. How many subject access requests you rejected in 2014?

5. How many subject access requests you rejected in 2015?

6. How many subject access requests you rejected in 2016?

7. What was the average cost for you to process a subject access request in 2014?

8. What was the average cost for you to process a subject access request in 2015?

9. What was the average cost for you to process a subject access request in 2016?

10. How much do you charge an individual to process a subject access request?

Click here for Response
17/10/2017 712/17

1. Names of all assessment centres to which adults in the CCG are referred for autism diagnostic assessments.

2. Number of patients of each gender who were referred to each centre for an autism assessment.

3. Number of patients of each gender who received a diagnosis of any form of autism or autism spectrum disorder from each centre.

Click here for Response
18/10/2017 713/17

1. What activities has Southern Derbyshire CCG undertaken to promote cervical screening and increase uptake over the last year (August 2016 - August 2017)?
a. What were the outcomes of those activities? For example, greater awareness, increased screening coverage.
b. Have local targets been set to improve cervical screening level?
c. Does your CCG have a budget to encourage uptake of cervical screening?

2. Are you aware of the report published by Jo’s Cervical Cancer Trust in January 2017, ‘Cervical Screening in the Spotlight: an audit of activities undertaken by local authorities and clinical commissioning groups to increase cervical screening coverage in England’? Yes / No
a. If yes, have any additional activities to improve cervical screening coverage been undertaken or planned as a result of the ‘Cervical Screening in the Spotlight’ report? If yes, can you outline what? 

3. Has your team accessed cervical screening programme coverage statistics (management information) in the GP data hub on NHS digital?

Click here for Response
23/10/2017 714/17

1. How many allegations of sexual assault and sexual harassment has your organisation received against GPs or CCG employees in each of the past four years?

2. In how many of the cases were any of the alleged victims aged 18 or under at the time of the alleged offence?

3. In how many of the cases were any of the alleged victims’ current or former patients?

4. For each case, did it lead to i) internal disciplinary proceedings, ii) external disciplinary proceedings (i.e. through a regulator) and/or iii) a financial settlement?

5. For each case, please provide a broad description of the allegations involved, including the number of alleged victims/alleged perpetrators; their age (within a 10-year band); the date of the alleged offence and whether the alleged perpetrator occupied a managerial position.

6. For each case, please list the gender of the alleged perpetrator and the alleged victim. Alternatively, provide totals for the genders of the alleged perpetrators and alleged victims across all of your cases.

7. For each case which was dealt with by disciplinary proceedings, how many alleged offenders were i) fired; ii) suspended, iii) received written or verbal warnings.

8. Please provide the value of any financial settlement in each case.

9. Did any settlements (financial or otherwise) include clauses placing any restriction on the ability of the alleged victim to discuss the events involved? If so, how many?

Click here for Response
25/10/2017 715/17

1. Does your CCG commission services for chronic migraine?

2. If your CCG does commission chronic migraine services who are the providers commissioned to provide these services?

Click here for Response
26/10/2017 716/17

1. In relation to the current financial year (17/18) could you please provide me with information relating to the first 20 occasions in which you sanctioned the use of a patient’s Personal Health Budget (PHB) to be spent on something that was NOT for the provision of care, medicine, or transport to a place where care or medicine was provided?

2. For each of these 20 occasions please state (i) what the money was spent on and (ii) how much money was spent on it and (iii) what was the outcome the patient was working towards as a result of this spend?

3. How many PHBs for individual patients were in operation in the 2016/17 financial year and what was the total cost of them?

Click here for Response

Click here for Attachment

27/10/2017 717/17

The figures for how much CCG (Clinical Commissioning Group) spend has been appointed for the following areas for 2016/17 and 2017/18:

  • Complex equipment for children with disability
  • Mild-moderate equipment for children with disability
Click here for Response
29/10/2017 718/17

1. What is the total number of APMS contracts held by the CCG?

2. What is the Date of renewal against each APMS contract?

3. When will tender processes begin for each APMS contract?

4. What is the value and value calculation for any APMS contract?

5. Are you partnered with a GP federation?

Click here for Response
30/10/2017 719/17

1. Has the CCG budgeted to provide full transformational funding to general practice by the end of 2018/19?

2. If so, how much of this transformational funding is the CCG planning on providing to general practice:
a. Per head for 2017/18?
b. In total for 2017/18?
c. Per head for 2018/19?
d. In total for 2018/19? 

3. If the CCG cannot provide the full transformational funding by the end of 2018/19, what is the main reason this?

Click here for Response
25/10/2017 720/17

1. Have any IFRs been accepted by the South Derbyshire CCG for Freestyle Libre/Flash Glucose Monitoring in 2017?

2. What would be the criteria for accepting rejecting the IFR?

Click here for Response
Last modified: 21/11/2017